🟢 Neuroone Medical Technologies is trading 7.1% up in after-hours trading after its first pharmaceutical-industry purchase order

Neuroone Medical Technologies is trading at $1.05, up 7.14% in after-hours trading after announcing on October 22, 2026, its first pharmaceutical-industry purchase order for its StereoCED drug-delivery platform.

• The order supports preclinical animal research for a Tier 1 global pharmaceutical company; the study is expected to begin in large animals early next year.
• StereoCED is not FDA-cleared or approved; the order is for research, not an approved clinical product.